Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Free Report) - Stock analysts at HC Wainwright lifted their FY2028 earnings per share (EPS) estimates for shares of Verrica Pharmaceuticals in a research report issued to clients and investors on Tuesday, April 8th. HC Wainwright analyst O. Livnat now expects that the company will post earnings of $0.11 per share for the year, up from their previous forecast of $0.06. HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Verrica Pharmaceuticals' current full-year earnings is ($1.46) per share. HC Wainwright also issued estimates for Verrica Pharmaceuticals' FY2029 earnings at $0.18 EPS.
Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01. The company had revenue of $0.34 million for the quarter, compared to analyst estimates of $1.30 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%.
Separately, Needham & Company LLC reiterated a "hold" rating on shares of Verrica Pharmaceuticals in a report on Wednesday, April 9th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $9.50.
Check Out Our Latest Analysis on VRCA
Verrica Pharmaceuticals Stock Performance
Shares of NASDAQ:VRCA traded up $0.04 during trading on Wednesday, reaching $0.52. 249,091 shares of the stock were exchanged, compared to its average volume of 578,273. Verrica Pharmaceuticals has a 12-month low of $0.38 and a 12-month high of $11.41. The firm's 50-day moving average price is $0.60 and its 200 day moving average price is $0.86. The firm has a market cap of $48.18 million, a price-to-earnings ratio of -0.29 and a beta of 1.68.
Institutional Trading of Verrica Pharmaceuticals
Hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. acquired a new stake in shares of Verrica Pharmaceuticals during the 4th quarter valued at approximately $32,000. Barclays PLC lifted its position in shares of Verrica Pharmaceuticals by 404.6% in the 3rd quarter. Barclays PLC now owns 31,341 shares of the company's stock worth $45,000 after buying an additional 25,130 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Verrica Pharmaceuticals in the 3rd quarter valued at about $87,000. Verition Fund Management LLC bought a new stake in shares of Verrica Pharmaceuticals during the 3rd quarter valued at about $89,000. Finally, Jane Street Group LLC raised its stake in Verrica Pharmaceuticals by 106.5% during the third quarter. Jane Street Group LLC now owns 69,872 shares of the company's stock worth $101,000 after acquiring an additional 36,028 shares during the period. 42.45% of the stock is owned by institutional investors.
About Verrica Pharmaceuticals
(
Get Free Report)
Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
Featured Stories
Before you consider Verrica Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verrica Pharmaceuticals wasn't on the list.
While Verrica Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
